Bone marrow aplasia - A rare complication of imatinib therapy in CML patients

American Journal of Hematology

Volumn 82, Issue 4, 2007, Pages 314-316

  Srinivas, Upendra ^a   Pillai, Lakshmi S ^a   Kumar, Rajat ^a   Pati, H P ^a   Saxena, Renu ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bone marrow aplasia; Imatinib therapy

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW APLASIA; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PANCYTOPENIA; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT DURATION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BLAST CRISIS; BONE MARROW EXAMINATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PANCYTOPENIA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 34147170473     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20776     Document Type: Article

References (9)

1. Jorgensen HG, Copland M, Holyoake TL. Granulocyte-colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 2005;103:210-211.
2. Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia. Leuk Res 2004;28:613-618.
3. Al Aly Z, Philoctete AJM, Gellens ME, Gonzalez EA. Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: True association or mere coincidence? Am J Kidney Dis 2005;45:762-768.
4. Song KW, Rifkind J, Al-Beirouti B, et al. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma 2004;45:1633-1636.
5. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004100:116-121.
6. Jiang Q, Chen S, Jiang B, et al. Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients. Beijing Da Xue Xue Bao 2003;18:136-140.
7. Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma 2005;46:781-784.
8. Chng WJ, Tan LH. Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia. Leuk Res 2005;29:719-720.
9. Sumi M, Tauchi T, Shimamoto T, et al. Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy. Rinsho Ketsueki 2002;43:868-870.